IONS PDUFA decision: Tuesday, September 22, 2026

…adults with Alexander disease (AxD), assuming approval   o New Drug Application (NDA) under FDA Priority Review with PDUFA target action date of September 22, 2026   o Entered a license agreement with Recordati to develop and commercialize zilganersen outside the U.S.   • Obuda

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.